Advion Adds API 5000 and API 4000 Mass Spectrometers from Applied Biosystems/MDS Analytical Technologies

Advion BioServices, Inc. has announced that it has expanded its bioanalytical service capabilities by adding five new triple quadrupole mass spectrometers to its laboratory in Ithaca, New York.

Included in this investment are API 5000™ LC/MS/MS System and API 4000™ LC/MS/MS System from Applied Biosystems/MDS Analytical Technologies.

With this purchase, Advion brings its total of new mass spectrometers acquired in the past year to seven. These additional instruments provide Advion with increased LC/MS capacity to meet growing client demands and the ability to provide its clients with an expanding array of bioanalytical services.

According to Jack Henion, PhD, Chief Scientific Officer, Advion, “Utilizing state-of-the-art instrumentation is an important focus for Advion. We are committed to remaining leaders of scientific excellence in bioanalysis and the purchase of these mass spectrometers exemplifies this focus.”

The Company says that the API 5000 and API 4000 systems provide the company with the sensitivity and selectivity in analysis necessary to obtain precise testing results. The API 5000 System is ideal for the detection of low-level molecules. It couples liquid chromatography with Applied Biosystems/MDS Analytical Technologies’ QJet™ ion source technology and triple quadrupole tandem mass spectrometry (LC/MS/MS), a widely used laboratory technique for measuring pharmaceutical compounds and metabolites.

Tom Kurz, President of Commercial Operations, comments, “The increased capacity and flexibility afforded by this investment will allow us to better serve our clients’ need for timely bioanalytical services of the highest quality.”